VKVinod Khatri

Vinod Khatri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vinod Khatri has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Heteromultivalente Nanogele als hochwirksame Inhibitoren von Pseudomonas aeruginosa

    by Yuhang Jiang, Chuanxiong Nie, Boyu Zheng, Vinod Khatri, Denis Puccio, Yanping Long, Mathias Dimde, Rainer Haag, Sumati Bhatia

    Zusammenfassung: Die zunehmende Verbreitung mikrobieller Resistenzen erfordert neue antibakterielle Konzepte zur gezielten Erkennung und Abtötung pathogener Bakterien. In dem vorliegenden Artikel stellen wir die Synthese eines heteromultivalenten Nanogelsystems gegen Pseudomonas aeruginosa ( P. aeruginosa ) vor. Diese Nanogele basieren auf biokompatiblen Polyglycerinen und sind mit den Zuckerliganden Fucose (Fuc) bzw. Galactose (Gal) funktionalisiert, um P. aeruginosa gezielt anzugreifen. Durch eine weitere Modifikation dieser Nanogele mit den kurzkettigen Peptiden BMAP‐18 (GRFKRFRKKFKKLFKKLS) konnten wir eine Inaktivierung von über 99,99 % planktonischer sowie über 99,9 % biofilmbeschichteter P. aeruginosa innerhalb von 12 Stunden Behandlung erreichen. Darüber hinaus zeigt das System ein breites antimikrobielles Wirkungsspektrum und hemmt wirksam Escherichia coli sowie Methicillin‐resistente Staphylococcus aureus (MRSA). Dieses modulare Design bietet eine vielversprechende Strategie für die Entwicklung neuartiger antimikrobieller Therapien, die auf biofilmassoziierte Infektionen und multiresistente Bakterien (MDR) abzielen.

  • Open Access

    Heteromultivalent Nanogels as Highly Potent Inhibitors of Pseudomonas Aeruginosa

    by Yuhang Jiang, Chuanxiong Nie, Boyu Zheng, Vinod Khatri, Denis Puccio, Yanping Long, Mathias Dimde, Rainer Haag, Sumati Bhatia

    The increasing prevalence of microbial resistance requires new antibacterial concepts for selective targeting and killing of pathogenic bacteria. Here, we report the synthesis of a heteromultivalent nanogel system against Pseudomonas aeruginosa ( P. aeruginosa ). These nanogels are based on biocompatible polyglycerols and functionalized with sugar ligands fucose (Fuc) or galactose (Gal) for P. aeruginosa targeting. With a further modification of these nanogels with BMAP‐18 short chain peptides (GRFKRFRKKFKKLFKKLS), we have achieved > 99.99% inactivation of planktonic and > 99.9% inactivation of biofilm‐coated P. aeruginosa within 12 h of treatment. Additionally, the system demonstrates broad‐spectrum antimicrobial potential, effectively inhibiting Escherichia coli ( E. coli ) and Methicillin‐resistant Staphylococcus aureus (MRSA). This modular design offers a promising strategy for the development of next‐generation antimicrobial therapies targeting biofilm‐associated infections and MDR bacteria.


  • Open Access

    Polysialosides Outperform Sulfated Analogs for Binding with SARS‐CoV‐2

    by Vinod Khatri, Nico Boback, Hassan Abdelwahab, Daniela Niemeyer, Tahlia M. Palmer, Anil Kumar Sahoo, Yannic Kerkhoff, Kai Ludwig, Julian Heinze, Dilara Balci, et al.

    Both polysialosides and polysulfates are known to interact with the receptor binding domain (RBD) of the SARS‐CoV‐2 spike protein. However, a comprehensive site by site analysis of their binding affinities and potential synergistic antiviral effects have not been performed. Here, we report on the synthesis of polysialosides with nanomolar binding affinities to spike proteins of SARS‐CoV‐2 in solution using microscale thermophoresis. The dendritic polyglycerol based polysialosides dPG500SA0.55 and dPG500SA0.25, with a dissociation constant Kd of 4.78 nm and 10.85 nm, respectively, bind ≈500 times stronger than the high density polysulfated analog dPG500S0.55, to intact SARS‐CoV‐2 virus particles or isolated spike protein. In fact, the presence of sulfate groups in a heteromultivalent compound dPG500SA0.20S0.20 weakens the binding to spike proteins. A polycarboxylated analog does not bind to SARS‐CoV‐2, ruling out that the interaction of polysialoside is simply driven by electrostatics. Using explicit‐solvent all‐atom molecular dynamics simulations and ensemble docking studies, atomistic details are obtained on the interaction of different functional groups with the SARS‐CoV‐2 RBD. The data support the conclusion that sialosides interact stronger than sulfates for their binding with RBD of SARS‐CoV‐2. Notably, the most affine binder dPG500SA0.55 inhibits SARS‐CoV‐2 (WT, D614G) replication up to 98.6% at 0.5 µm concentrations.


  • Open Access

    Polysialosides outperform sulfated analogs for the inhibition of SARS-CoV-2

    by Vinod Khatri, Nico Boback, Hassan Abdelwahab, Daniela Niemeyer, Tahlia M. Palmer, Anil Kumar Sahoo, Yannic Kerkhoff, Kai Ludwig, Dilara Balci, Jakob Trimpert, et al.

    Both polysialosides and polysulfates are known to interact with the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. However, a comprehensive site by site analysis of their binding affinities and potential synergistic antiviral effects have not been performed. Here, we report on the synthesis of polysialosides with nanomolar binding affinities to spike proteins of SARS-CoV-2 in solution using microscale thermophoresis (MST). The dendritic polyglycerol based polysialosides dPG500(SA)0.55 and dPG500(SA)0.25, with a dissociation constant Kd of 4.78 nM and 10.85 nM, respectively, bind ~500 times stronger than the high density polysulfated analog dPG500(OSO3Na)0.55, to intact SARS-CoV-2 virus particles or isolated spike protein. In fact, the presence of sulfate groups in a heteromultivalent compound dPG500(SA)0.20(OSO3Na)0.20 weakens the binding to spike proteins. A polycarboxylated analog does not bind to SARS-CoV-2, ruling out that the interaction of polysialoside is simply driven by electrostatic interactions. Furthermore, we found potent nanomolar binding of dPG500(SA)0.55 to SARS-CoV-2 variant B.1.617 (Delta) and B.1.1.529 (Omicron) RBD. Using explicit-solvent all-atom molecular dynamics (MD) simulations and docking studies, we obtain atomistic details on the interaction of different functional groups with the SARS-CoV-2 RBD and their binding affinities. Our data support the conclusion that sialosides interact stronger with RBD than sulfates. Notably, our most affine binder dPG500(SA)0.55 inhibits SARS-CoV-2 (WT, D614G) replication up to 98.6% at low nanomolar concentrations.

  • Synthesis of substituted 2H-Chromenes via Pd-catalyzed C–H activation and thermal cyclization

    by Vipin K. Maikhuri, Vineet Verma, Divya Mathur, Ashok K. Prasad, Vinod Khatri